NSABP and GBG are pleased to announce the 1000th patient has been randomized for the GeparDouze trial.
On November 5th site 9008, Bon Secours, randomized the 1000th patient to the trial. Congratulations to Site 9008 Bon Secours, Dr. William Irvin, Principal Investigator at the site, and Mary Kate Williams and Melissa Godsey on helping us accomplish this milestone!
As of November 5th there are 1001 patients randomized to the trial. This is an amazing milestone that we could not have reached without our dedicated investigators and research staff at all the sites.
Thank you for ongoing support of the B-59/GBG-96 trial!